Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Today 13:02
BRIEF-Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA Oct 22 (Reuters) - Biohaven Ltd. BHVN.N:
BIOHAVEN - FDA ACCEPTS BIOHAVEN NDA RESUBMISSION FOR VYGLXIA (TRORILUZOLE) IN SCA - SEC FILING
Source text: [ID:n0001935979-26-000083]
Further company coverage: BHVN.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean